Funding Evidence: The National Institute of Neurological Disorders and Stroke Clinical Trials Program

AUTOR(ES)

Ravina, Bernard

FONTE

The American Society for Experimental NeuroTherapeutics

RESUMO

Summary: The goal of the National Institute of Neurological Disorders and Stroke (NINDS) Clinical Trials Program is to foster clinical trials that will provide the evidence needed to inform clinical care. The NINDS currently supports clinical research in over 150 neurological disorders. The rapid pace of preclinical discovery and the diversity of neurological diseases, however, present challenges for clinical trials. There is a growing number of potential interventions to be tested in clinical trials. The NINDS Clinical Trials program is therefore exploring ways of making drug selection for clinical trials more evidence-based. Additionally, NINDS supports pilot clinical trials that focus on the timely and efficient testing of agents to determine if resource-intensive comparative efficacy trials are warranted. In concert with the National Institutes of Health Roadmap, NINDS is planning to expand clinical trials infrastructure. This infrastructure is intended to enable the conduct of clinical trials for rare diseases and diseases without previous trials experience and facilitate the recruitment of a broad range of participants. Rigorous programs to select agents, and design and monitor clinical trials will encourage the efficient use of this clinical trials infrastructure and will ensure that NINDS-funded studies meet the highest scientific and ethical standards.

Documentos Relacionados

• Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research
• Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials
• The Neurological Information Network of the National Institute of Neurological Diseases and Blindness *
• Clinical effectiveness and cost effectiveness of zanamivir (Relenza): translating the evidence into clinical practice, a National Institute for Clinical Excellence view.
• National stroke surveillance program needed in Canada